Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals to Host R&D Day on October 11, 2018
CAMBRIDGE, Mass. , Oct. 04, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA)  today announced that it will host a live webcast of its R&D Day on Thursday, October 11, 2018 beginning at 8:30 am ET . The event is being held in New York, NY .
View HTML
Toggle Summary Momenta Pharmaceuticals Completes Strategic Review to Refocus its Operations and Drive Shareholder Value
    -- Company to Prioritize Pipeline of Novel Drug Candidates for Immune-Mediated Diseases and Reduce Investment in Biosimilars by Focusing on Two Later-stage Assets -- -- Company to Streamline Operations Through Corporate Restructuring -- CAMBRIDGE, Mass. , Oct.
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Second Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the second quarter ended June 30, 2018 and provided a corporate update. “The strategic review of our business announced earlier this year is progressing and we
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Second Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , Aug. 02, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA), today announced that it will release its financial results for the second quarter ended June 30, 2018 and provide a corporate update before the U.S. financial markets open on Thursday, August 9 ,
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Goldman Sachs 39th Annual Global Healthcare Conference
CAMBRIDGE, Mass. , June 06, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will present at the Goldman Sachs 39th Annual Global Healthcare Conference .  The presentation is scheduled for Wednesday, June 13, 2018 at 2:40 P.M. PT / 5:40 P.M. ET .
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Presentation on M281, an Anti-FcRn Monoclonal Antibody, at 11th International Congress on Autoimmunity
CAMBRIDGE, Mass. , May 17, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced the upcoming presentation describing the broad potential for anti-FcRn therapeutics and the discovery of M281. The presentation will be part of the 11 th International Congress on
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch Health Care Conference 2018
CAMBRIDGE, Mass. , May 10, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will present at the Bank of America Merrill Lynch Health Care Conference 2018.  The
View HTML
Toggle Summary Momenta Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass. , May 08, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2018 and provided a corporate update. “We made important progress in the first quarter of 2018 across our complex generic,
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of First Quarter 2018 Financial Results Conference Call and Webcast
CAMBRIDGE, Mass. , May 01, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), today announced that it will release its financial results for the first quarter ended March 31, 2018 and provide a corporate update before the U.S. financial markets open on Tuesday, May 8 , 2018.   
View HTML
Toggle Summary Momenta Pharmaceuticals to Webcast Presentation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass. , March 05, 2018 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences.
View HTML